Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Rat (Rattus) Antikörper:
anti-Mouse (Murine) Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Vif (zeige BTG1 Antikörper) proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3G (zeige APOBEC3G Antikörper).
simian immunodeficiency virus (SIV) Vif (zeige BTG1 Antikörper) binds to and requires CBF-beta to degrade rhesus macaque APOBEC3G (zeige APOBEC3G Antikörper)
Cbfbeta knockdown mice also exhibited decreased expression of key genes within the corpora lutea and morphological changes in the ovarian structure, including the presence of large antral follicles well into the luteal phase. Overall, these data suggest a role for CBFs as significant regulators of gene expression, ovulatory processes, and luteal development in the ovary.
Chd7 (zeige CHD3 Antikörper) deficiency delays leukemia initiation induced by Cbfb-MYH11 (zeige MYH11 Antikörper).
results indicate that modulations in the relative levels of the isoforms may adjust transcriptional activation by Runx2 (zeige RUNX2 Antikörper) to appropriate physiological levels. Cbfb2 was more abundant, but Cbfb1 was more potent for enhancing Runx2 (zeige RUNX2 Antikörper) activity. Although only Cbfb2 loss generated overt skeletal phenotypes, both may play major roles in skeletal development with functional redundancy
High CBFB expression is associated with leukemia.
Vif (zeige BTG1 Antikörper) stabilization by CBFbeta is mainly caused by impairing MDM2 (zeige MDM2 Antikörper)-mediated degradation.
the mechanistic view that the proliferative function of Crlz-1 (zeige UTP3 Antikörper) is caused by relaying Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) to pre-B cell receptor signaling pathways through the regulation of Runx/CBFbeta heterodimerization was verified
Core binding factor beta deficiency in chondrocytes caused a decrease of protein levels of Runx transcription factors by accelerating polyubiquitination-mediated proteosomal degradation in vitro
Cbfb plays an important role in the stabilization of Runx family proteins; and that Runx2 (zeige RUNX2 Antikörper) protein stability is less dependent on Cbfb in calvariae than in cartilaginous limb skeletons
findings indicate that Cbfbeta stabilizes Runx2 (zeige RUNX2 Antikörper) in osteoblasts by forming a complex and thus facilitates the proper maintenance of bone mass, particularly cortical bone
Runx/Cbfb signaling regulate androgen receptor (zeige AR Antikörper) pathway, but does not affect the circulating testosterone levels or the enzymatic conversion to DHT.
In neuronal fate determination, Runx co-factor Cbfbeta is essential for its function, but the high level of Runx3 (zeige RUNX3 Antikörper) expression can overcome the loss of Cbfbeta, demonstrating that Cbfbeta in this context serves solely as a signal amplifier of Runx3 (zeige RUNX3 Antikörper) activity.
characterization of cbfbeta gene
Our data suggest that runx1 and cbfb are required at 2 different steps during early hematopoietic stem cell development
Data demonstrate for the first time an essential role of JunB (zeige JUNB Antikörper)-CBFbeta signaling for maintaining sarcomere architecture and function.
the presented study demonstrates that CBFB-MYH11-based MRD status during the first 3 months after allo-HCT, but not KIT mutations, can be used to identify patients with a high risk of relapse.
discussion of the role of CBFB in diseases caused by their mutations or deletions (review)
The co-existence of BCR (zeige BCR Antikörper)-ABL1 (zeige ABL1 Antikörper) and CBFB rearrangement is associated with poor outcome and a clinical course similar to that of CML (zeige BCR Antikörper)-BP, and unlike de novo AML (zeige RUNX1 Antikörper) with CBFB rearrangement, suggesting that high-intensity chemotherapy with TKI should be considered in these patients.
Moreover, using a CBF-beta loss-of-function mutant, the authors demonstrated that the interaction between CBF-beta and Vif (zeige BTG1 Antikörper) was not sufficient for Vif (zeige BTG1 Antikörper) assistance; a region including F68 in CBF-beta was also required for the stability and function of Vif (zeige BTG1 Antikörper).
Mutational analysis of CBFbeta revealed that F68 and I55 (zeige FBXL14 Antikörper) residues are important and participate in a tripartite hydrophobic interaction with W5 of Vif (zeige BTG1 Antikörper) to maintain a stable and functional Vif (zeige BTG1 Antikörper)-CBFbeta complex.
Thus, an NGF (zeige NGFB Antikörper)/TrkA (zeige NTRK1 Antikörper)-MAPK (zeige MAPK1 Antikörper)-CBFbeta pathway converges with Islet1 (zeige ISL1 Antikörper)-Runx1 (zeige RUNX1 Antikörper) signaling to promote Runx1 (zeige RUNX1 Antikörper)/CBFbeta holocomplex formation and nonpeptidergic nociceptor maturation.
Our findings demonstrate that HSPCs exposed to non-cytotoxic levels of environmental chemicals and chemotherapeutic agents are prone to topoisomerase II (zeige TOP2 Antikörper)-mediated DNA damage at the leukemia-associated genes MLL (zeige MLL Antikörper) and CBFB.
These results provide important information on the assembly of the Vif (zeige BTG1 Antikörper)-CUL5 (zeige CUL5 Antikörper)-E3 ubiquitin ligase (zeige MUL1 Antikörper) and identify a new viV binding interface with CBF-beta at the C-terminus of HIV-1 Vif (zeige BTG1 Antikörper).
CBF-beta promoted steady-state levels of HIV-1 Vif (zeige BTG1 Antikörper) by inhibiting the degradation of HIV-1 Vif (zeige BTG1 Antikörper) through the proteasome pathway.
The protein encoded by this gene is the beta subunit of a heterodimeric core-binding transcription factor belonging to the PEBP2/CBF transcription factor family which master-regulates a host of genes specific to hematopoiesis (e.g., RUNX1) and osteogenesis (e.g., RUNX2). The beta subunit is a non-DNA binding regulatory subunit\; it allosterically enhances DNA binding by alpha subunit as the complex binds to the core site of various enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers and GM-CSF promoters. Alternative splicing generates two mRNA variants, each encoding a distinct carboxyl terminus. In some cases, a pericentric inversion of chromosome 16
core binding factor beta
, core-binding factor subunit beta
, core-binding factor, beta subunit
, core binding factor beta subunit
, SL3-3 enhancer factor 1 subunit beta
, SL3/AKV core-binding factor beta subunit
, polyomavirus enhancer-binding protein 2 beta subunit
, CCAAT-binding transcription factor subunit B
, core-binding factor beta
, SL3-3 enhancer factor 1 beta subunit
, polyomavirus enhancer binding protein 2, beta subunit
, CAAT box DNA-binding protein subunit A
, CAAT-box DNA-binding protein subunit A
, nuclear transcription factor Y subunit A
, nuclear transcription factor Y subunit alpha
, CAAT box DNA-binding protein subunit B
, CAAT-box DNA-binding protein subunit B
, CCAAT binding transcription factor of CBF-B/NFY-B
, CCAAT-binding transcription factor subunit A
, nuclear transcription factor - Y beta
, nuclear transcription factor Y subunit B
, nuclear transcription factor Y subunit beta